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Abstract
Background & Aim
Alpha-amylase in both blood and saliva has been used as a diagnostic parameter. While
studies examining alpha-amylase activity in saliva have shown that it is sensitive to physio-
logical and psychological challenge of the adrenergic system, no challenge studies have
attempted to elucidate the role of the adrenergic system in alpha-amylase activity in blood.
We set out to examine the impact of psychological and pharmacological challenge on
alpha-amylase in blood in two separate studies.
Methods
In study 1, healthy subjects were examined in a placebo-controlled, double-blind paradigm
using yohimbine, an alpha2-adrenergic antagonist. In study 2, subjects were examined in a
standardized rest-controlled psychosocial stress protocol. Alpha-amylase activity in blood
was repeatedly measured in both studies.
Results
Results of study 1 showed that alpha-amylase in blood is subject to stronger increases after
injection of yohimbine compared to placebo. In study 2, results showed that there was no
significant effect of psychological stress compared to rest.
Conclusions
Alpha-amylase in blood increases after pharmacological activation of the adrenergic path-
ways suggesting that sympathetic receptors are responsible for these changes. Psychologi-
cal stress, however, does not seem to have an impact on alpha-amylase in blood. Our
findings provide insight into the mechanisms underlying activity changes in alpha-amylase
in blood in healthy individuals.
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Introduction
Alpha-amylase is an enzyme that hydrolyzes internal alpha-1,4 glycoside bonds, resulting in
the production of maltose and oligosaccharides. Amylase concentrations are highest in the
pancreas and the salivary glands, although amylase is abundant in other organs as well. The sal-
ivary and pancreatic forms of alpha-amylase have gained interest in a variety of areas [1]. Mea-
surement of salivary alpha-amylase activity has been proposed to reflect stress-related changes
in the adrenergic system [2]. Studies using physiological [3, 4] and psychological stressors [5,
6] revealed increased activity of salivary alpha-amylase due to stress. Studies in humans have
shown that alpha2-adrenergic [7] and beta-adrenergic [8] mechanisms are involved in
increases of salivary alpha-amylase activity. Studies from our work group show that amylase
activity in saliva is highly sensitive to psychological stressors and might thus be considered an
easily measured non-invasive parameter to evaluate stress responses [9, 10]. On the other
hand, measurement of alpha-amylase in blood has been used for the confirmation of acute
pancreatitis and disease activity in a number of other conditions. Elevation of amylase levels in
serum is a major indicator for acute pancreatitis, though controversial regarding its specificity
[11–15].
Whereas salivary amylase is produced by the salivary glands and is released predominantly
upon adrenergic innervation, amylase in blood is mostly produced and released by the pan-
creas. Pancreatic amylase enters the blood stream and can easily be measured in blood [16].
Pancreatic amylase was found in serum after beta-adrenergic stimulation [17]. However, unex-
plained elevations in serum alpha-amylase have caused puzzlement with regard to the etiology
of these changes [18, 19].
Taken together, alpha-amylase in both blood and saliva has been used as a diagnostic
parameter. Although amylase in serum is often measured as an indicator for acute pancreatitis,
debates about its validity are found in the literature. Furthermore, since the salivary component
of the enzyme has found to be subject to stress-related changes, one has to consider possible
confounding values also in blood amylase due to stressful events, particularly given the involve-
ment of the adrenergic system in the release of pancreatic amylase. We therefore set out to
measure alpha-amylase activity in the blood in laboratory settings in which subjects were
exposed to 1) a pharmacological and 2) a psychological challenge, both being believed to acti-
vate the adrenergic system, in two independent studies. We hypothesized that both a pharma-
cological and a psychological stimulation of the adrenergic system would elicit significant
increases in alpha-amylase in blood.
Methods
Participants
In the first study (pharmacological challenge), a total of 13 healthy male subjects took part in
the experiment. In the second study (psychological challenge), 32 healthy male subjects (not
identical with subjects from the first study) participated. The following applies to participants
of both studies:
All participants were recruited at the University of Zurich and the Swiss Federal Institute of
Technology, Zurich, by electronic mail and/or advertisement. They received a screening ques-
tionnaire, containing exclusion criteria designed to reduce confounding factors that have been
shown to affect physiological dependent variables. All subjects were medication-free. Further-
more, subjects were non-smokers, since smoking has been shown to increase serum amylase
activity [20]. Participants were told not to perform any strenuous physical activity 48 hours
prior to the experiment and to cease all sporting activities during the time of the study. Intake
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of ethanol and caffeine was forbidden 18 hours prior to the experiments. At least 60 minutes
before the examinations, subjects were not allowed to eat and to take low pH soft drinks. Addi-
tionally, all subjects underwent a full health examination by a physician (study 1) or were
screened for any health problems by a member of the study group (study 2). Subjects with any
acute or chronic somatic or psychiatric disorder were excluded. After the subjects were pro-
vided with complete written and oral descriptions of the respective study, written informed
consent was obtained. In both studies, the subjects were remunerated for participation. The
study protocols were formally approved by the ethics committee of the University of Zurich
and the ethics committee of the Canton of Zurich.
Procedures
Pharmacological challenge. The effect of the alpha2-adrenergic receptor antagonist
yohimbine on alpha-amylase activity in blood was determined in a randomized double-blind
placebo controlled study. Fourty-five minutes prior to intravenous injection, a catheter line
was inserted, which was kept patent by infusion of saline. Two samples were drawn before the
injection (-20 and -10 minutes) of yohimbine hydrochloride (0.4 mg/kg) or 0.9% NaCl, respec-
tively, and six additional samples were collected following the injection (+10, +20, +30, +60,
+90, and +120 minutes). Alpha-amylase was determined from these samples (see below). The
two conditions took place with a minimum of 14 days in between. All procedures were per-
formed between 1300hours and 1700hours. Subjects were randomized into two groups, with
group 1 undergoing first the placebo condition and group two undergoing first the yohimbine
condition, to control for possible sequence effects between the two conditions.
Psychological challenge. A standardized psychosocial stress protocol was used. The Trier
Social Stress Test (TSST) has repeatedly been found to induce profound psychological and
physiological responses in 70–80% of the subjects tested [21]. Subjects were introduced to the
TSST (two minutes). Afterwards, they had ten minutes to prepare their free speech, before sub-
jects were exposed to a simulated job interview (five minutes) followed by a mental arithmetic
task (five minutes) in front of an audience. Blood samples (by the indwelling venous catheter)
were taken immediately before and after the TSST, with further samples taken at 15, 30, and 60
minutes to assess alpha-amylase. The stress and rest conditions were completed with a mini-
mum of 14 days in between. The TSST was performed between 1300hours and 1700hours. Sub-
jects were randomized into two groups, with group 1 undergoing first the rest condition and
group two undergoing first the stress condition, to control for possible sequence effects
between the two conditions.
Measures
Blood was collected in EDTA-coated monovette (Sarstedt, Sevelen/Switzerland) collection
devices. After centrifugation at 3000 rpm for 10 min, plasma was aliquoted in pre-cooled plas-
tic tubes. Plasma amylase has been shown to be highly correlated to serum amylase [22, 23].
Samples were stored at –80°C until biochemical analysis took place. After thawing, samples
were centrifuged again at 3000 rpm for 5 minutes. Amylase activity was expressed as enzyme
level per volume of blood (enzymatic units per liter, U/l). Alpha-amylase activity was deter-
mined by using an automatic analyser (Cobas Mira) and assay kits obtained from Roche. The
reagents in the kit contain the substrate 2-chloro-4-nitrophenyl maltotrioside which is hydro-
lysed by alpha-amylase and directly produces 2-chloro-4-nitrophenol (CNP). The rate of pro-
duction of 2-chloro-4-nitrophenol, measured by the variation in absorbance per minute, is
proportional to the alpha-amylase activity. The activity is determined by measuring the
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absorbance at 405nm. The assay is a kinetic colorimetric test. Inter- and intra-assay variance
was below 1% in analyses of all of the experiments described in this paper.
Statistical analyses
Differences between conditions were calculated with general lineal models and Student’s t-
tests. ANOVAs for repeated measures were computed to reveal possible time and condition
effects. All reported results were corrected by the Greenhouse-Geisser procedure where appro-
priate (violation of sphericity assumption). For alpha-amylase, area under the total response
curve (AUC Total), expressed as area under all samples, as well as area under the response
curve with respect to increase (AUC Increase), was calculated using the trapezoid formula [24].
Data were tested for normal distribution and homogeneity of variance using a Kolmogorov-
Smirnov and Levene´s test before statistical procedures were applied. Effect sizes for repeated
ANOVA (f2) were computed by the following formula: eta2 / 1—eta2. Effect sizes for group dif-
ferences (d) were computed as the difference between the means, M1—M2, divided by standard
deviation of either group. For all analyses, significance level was α = 5%. Unless indicated, all
results shown are means ± standard error of means (SEM).
Results
Sample characteristics
In the first study, thirteen healthy male subjects participated (subject characteristics: age
mean = 24.9 years, SD = 2.2 years; height mean = 180.0 cm, SD = 5.4 cm; weight mean = 73.5
kg, SD = 7.1 kg; BMI mean = 22.66, SD = 1.83).
In the second study, thirty-two healthy male subjects participated (subject characteristics:
age mean = 23.8 years, SD = 2.4 years; height mean = 182.27 cm, SD = 7.66 cm; weight
mean = 74.8 kg, SD = 9.22 kg; BMI mean = 22.48, SD = 1.98). Participation in the two studies
was mutually exclusive.
Pharmacological challenge
The administration of yohimbine resulted in significant changes of alpha-amylase over time (F
(2.12/25.49) = 10.27; p< 0.001; f2 = 0.86; 95% CI 39.9–65.58 U/l). In the placebo condition,
significant changes were also observed (F (3.58/42.99) = 4.22; p = 0.007; f2 = 0.35; 95% CI
41.32–66.72 U/l). Neither at –20 min (t12 = 1.55; p = 0.148), nor at +120 min (t12 = 0.25; p =
.804) differences in amylase activity occurred between the two conditions. There was no condi-
tion main effect (F (1.00/12.00) = 0.54; p = 0.479; f2 = 0.04). However, both the main effect of
time (F (2.49/29.85) = 12.20; p< 0.001; f2 = 1.02) and the interaction of condition x time were
significant (F (2.64/31.68) = 5.54; p = 0.005; f2 = 0.46).
The AUC Total of the two conditions did not differ significantly (t12 = 0.52; p = 0.610;
7549.96 U/l versus 7442.62 U/l; d = 0.04; 95% CI -339.16–553.85 U/l; Fig 1A). However, in the
AUC Increase, a significant difference occurred, with the yohimbine condition resulting in a
higher increase (t12 = -3.00; p = 0.011; 104.115 U/l versus 380.15 U/l; d = 0.93; 95% CI -476.7-
(-)75.38 U/l; Fig 1B).
Psychological challenge
The psychological stress test resulted in significant changes of alpha-amylase over time (F
(2.73/79.26) = 46.86; p< 0.001; f2 = 1.62; 95% CI 47.7–62.76 U/l). In the rest condition, signifi-
cant changes were also observed (F (1.62/48.61) = 12.66; p< 0.001; f2 = 0.42; 95% CI 46.65–
71.04 U/l). Neither at the beginning (t28 = -1.16; p = 0.25), nor at the end (t28 = -1.39;
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p = 0.18) of the stress protocol differences in amylase activity occurred between the two condi-
tions. There was no condition main effect (F (1.00/29.00) = 1.08; p = 0.31; f2 = 0.04), but a
main effect of time (F (1.75/50.77) = 38.28; p< 0.001; f2 = 1.32). Furthermore, the interaction
of condition x time was significant (F (2.52/72.93) = 4.31; p = 0.011; f2 = 0.15).
However, the AUC Total of the two conditions did not differ significantly (t29 = -1.03;
p = 0.31; 1900.03 U/l versus 2062.17 U/l; d = 0.17; 95% CI -483.52–159.23 U/l; Fig 1C), and nei-
ther did the AUC Increase (t29 = 0.32; p = 0.75; 82.24 U/l versus 75.33 U/l; d = 0.01; 95% CI
-36.91–50.73 U/l; Fig 1D).
Fig 1. Alpha-amylase activity during four experimental conditions: pharmacological challenge and placebo (A AUC total and B AUC increase), and
psychological challenge and rest (C AUC total and D AUC increase). Values are means (error bars indicate SEM).
doi:10.1371/journal.pone.0130449.g001
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Discussion
We found marked increases in alpha-amylase in blood after challenge with a sympathetic stim-
ulant (study 1), but not after a psychological stressor (study 2). Although significant time
effects were observed in both the placebo condition of study 1 and in the rest condition of
study 2, the effect sizes of the interventions (f2 yohimbine: 0.86, TSST: 1.62) markedly differed
from the effect sizes of the respective control conditions (f2 placebo: 0.35, rest: 0.42). These
results indicate that alpha-amylase in blood is subject to changes that are regulated by the
adrenergic system.
The present findings may be compared to our findings in salivary amylase activity after
challenge with a sympathetic stimulant [7] and psychological stress [9, 10]. This is interesting,
since several studies have shown that parotid isoamylase is a component of circulating amylase
(in addition to amylases originating from the pancreas and the liver also contributing to the
sum of enzyme activity in blood). In a recent study, it was shown that pilocarpine administra-
tion-induced parotid amylase discharge in rats was accompanied by an increase in serum isoa-
mylase levels [25]. The elevations found in our pharmacological study might be in part due to
an increase of alpha-amylase in the salivary glands. Overall, pancreatic isoamylase represents
around 40% of normal serum amylase activity [26]. With the analysis strategies used in the cur-
rent studies, no information can be obtained on the exact contribution of the pancreas. Further
studies should provide more in-depths analyses of specific amylase isoenzymes.
Alpha-amylase in blood has been studied as a diagnostic marker for differential pathological
processes. As discussed, it is most often used to determine acute pancreatitis [11–15]. But sev-
eral studies have used the enzyme in other conditions. In one study, e.g., total serum amylase
was determined in patients with cystic fibrosis (CF), control patients, and patients with
Shwachman's syndrome. The results demonstrate that the patients with Shwachman's syn-
drome had significantly lower total serum amylase than the other patient groups [27]. Also,
hyperamylasemia and parotid hypertrophy are conditions found in patients with eating disor-
ders [28–30]. One study examined serum amylase levels in 56 underweight anorectics, 24
weight-recovered anorectics, 23 normal-weight bulimics, and 31 volunteer women. Normal-
weight bulimic patients had significantly higher admission serum amylase values than controls.
The authors observed that modest increases of serum amylase values appear to be a conse-
quence of binge-vomit behavior and suggested that serial serum amylase determination may be
useful in monitoring the degree of patient abstinence in therapeutic programs [28]. In the
serum and saliva of 45 patients with eating disorders and in 30 normal controls, alpha-amylase
activity was measured. Of the 45 patients evaluated, 12 had restrictive anorexia nervosa, 13
were bulimic anorectics and 20 had bulimia nervosa. In all these groups, the mean alpha-amy-
lase values in serum and saliva were higher than that of the control group. In all patients with
eating disorders, the mean concentration and secretion of alpha-amylase in saliva were
increased [29]. Another study investigated the clinical relevance of amylase level monitoring as
an objective measure in diagnosis and assessment of treatment response in bulimia nervosa.
Thirty-three subjects with bulimia nervosa had serum levels of total and salivary amylase moni-
tored during an 8-week treatment trial. At the beginning of treatment, the average total amy-
lase level was within the upper limits of normal, whereas average salivary amylase levels were
abnormally high. During the course of treatment, there was a significant reduction in the aver-
age salivary isoenzyme to within the normal range. Significant reductions in amylase levels
were recorded in patients with good treatment outcome, but not in those with poor outcome.
Amylase levels were not significantly correlated with severity of bulimic symptoms. These
results do not justify the use of amylase assays as a routine diagnostic or monitoring test, but
isoenzyme monitoring may provide useful clinical information in selected cases [30]. Eating
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disorders are not the only pathological conditions related to changes in alpha-amylase levels.
Both pancreatic and salivary isoenzymes in serum were examined in a study with 12 Alzheimer
patients looking for the possibility of amylase as a marker of M3 activity associated with maxi-
mally tolerated dose of xanomeline tartrate. Overall amylase results were not significant; how-
ever, a trend for salivary amylase was found [31]. Taken together, alpha-amylase assessed in
blood has been used widely as a diagnostic marker in various conditions; however, the mecha-
nisms that underlying potential changes as well as the differential contribution of various
sources of amylase are still not well understood and require further research efforts.
In our study, we were able to show that alpha-amylase in blood increases after induction of
pharmacological activation of the adrenergic pathways. Further, since there were no discern-
able effects of psychological stress, it might be suggested that alpha-amylase levels in blood
determined in routine and emergency analyses are most likely not confounded by everyday
stressors or the small stress elicited by a venous puncture.
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